Abstract
Cancers still constitute an important health burden, due to their high incidence and mortality. The discovery and clinical implementation of novel sensitive diagnostic markers could improve treatment outcomes. Circulating cell-free DNA (ccfDNA) offers great promise for the development of new molecular biomarkers. However, the analysis of ccfDNA methylation poses significant challenges due to ccfDNA fragmentation and low concentration in the blood. Techniques which have recently been developed for liquid biopsy studies have been adapted to the detection of trace amounts of ccfDNA. This mini-review focuses on recent technological advances which allow the discovery of new sensitive and specific liquid biopsy cancer biomarkers based on DNA methylation detection.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.